CLINICAL OUTCOME AND SEVERITY OF CLOSTRIDIOIDES (CLOSTRIDIUM) DIFFICILE INFECTION AT A TERTIARY REFERRAL HOSPITAL IN BRAZIL.|https://dx.doi.org/10.1590/S0004-2803.230302023-36
Microbial ecology between Clostridioides difficile and gut microbiota.|https://dx.doi.org/10.12938/bmfh.2023-033
Clostridioides difficile infection in the allogeneic hematopoietic cell transplant recipient.|https://dx.doi.org/10.1111/tid.14159
Microbiome profile and calprotectin levels as markers of risk of recurrent Clostridioides difficile infection.|https://dx.doi.org/10.3389/fcimb.2023.1237500
Two Times Versus Four Times Daily Cephalexin Dosing for the Treatment of Uncomplicated Urinary Tract Infections in Females.|https://dx.doi.org/10.1093/ofid/ofad430
Effects of fecal microbiota transplantation for recurrent Clostridium difficile infection in children on kidney replacement therapy: a pilot study.|https://dx.doi.org/10.1007/s00467-023-06168-6
Antisense inhibition of RNA polymerase Î± subunit of Clostridioides difficile.|https://dx.doi.org/10.1128/spectrum.01755-23
Outcomes of high-dose oral beta-lactam definitive therapy compared to fluoroquinolone or trimethoprim-sulfamethoxazole oral therapy for bacteremia secondary to a urinary tract infection.|https://dx.doi.org/10.1017/ash.2023.435
Swiss expert opinion: current approaches in faecal microbiota transplantation in daily practice.|https://dx.doi.org/10.57187/smw.2023.40100
Atypical presentation of a rare disorder; idiopathic myointimal hyperplasia of mesenteric veins (IMHMV): Report of two cases.|https://dx.doi.org/10.1016/j.ijscr.2023.108839
Biofilm Formation of Clostridioides difficile, Toxin Production and Alternatives to Conventional Antibiotics in the Treatment of CDI.|https://dx.doi.org/10.3390/microorganisms11092161
Prevalence of Non-Toxigenic Clostridioides difficile in Diarrhoea Patients and Their Clinical Characteristics.|https://dx.doi.org/10.3390/antibiotics12091360
Safety and tolerability of frozen, capsulized autologous faecal microbiota transplantation. A randomized double blinded phase I clinical trial.|https://dx.doi.org/10.1371/journal.pone.0292132
The Intestinal Microbiome and the Metabolic Syndrome-How Its Manipulation May Affect Metabolic-Associated Fatty Liver Disease (MAFLD).|https://dx.doi.org/10.3390/cimb45090455
Clostridium scindens secretome suppresses virulence gene expression of Clostridioides difficile in a bile acid-independent manner.|https://dx.doi.org/10.1128/spectrum.03933-22
Correlation between the presence of a cecal appendix and reduced diarrhea severity in primates: new insights into the presumed function of the appendix.|https://dx.doi.org/10.1038/s41598-023-43070-5
Short-course empiric antibiotics in children undergoing allogeneic hematopoietic cell transplant.|https://dx.doi.org/10.1016/j.jtct.2023.09.011
Long-term Safety Outcomes of Fecal Microbiota Transplantation: Real-World Data over Eight Years from the Hong Kong FMT Registry.|https://dx.doi.org/10.1016/j.cgh.2023.09.001
A Potent and Narrow-Spectrum Antibacterial against Clostridioides difficile Infection.|https://dx.doi.org/10.1021/acs.jmedchem.3c01249
Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects against Clostridioides difficile infection challenge in vivo.|https://dx.doi.org/10.4291/wjgp.v14.i4.71
An open-label, randomized trial comparing fidaxomicin to oral vancomycin for the treatment of Clostridioides difficile infection in hospitalized patients receiving concomitant antibiotics for concurrent infections.|https://dx.doi.org/10.1093/cid/ciad606
Identification of Micrococcin P2-Derivatives as Antibiotic Candidates against Two Gram-Positive Pathogens.|https://dx.doi.org/10.1021/acs.jmedchem.3c01309
